Skip to main content
Lancet (London, England)
Mortality risk with dual antiplatelet therapy?
Dual antiplatelet therapy duration and mortality - Authors' reply.
Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis.
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Lifestyle changes and heart disease.
Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial.
Letter: Propranolol and digitalis.
